RCKTĀ – Rocket Pharmaceuticals, Inc.
Float Short %
15.71
Margin Of Safety %
Put/Call OI Ratio
0.26
EPS Next Q Diff
0.13
EPS Last/This Y
0.62
EPS This/Next Y
0.92
Price
3.16
Target Price
7.86
Analyst Recom
2.06
Performance Q
2.93
Relative Volume
0.45
Beta
0.6
Ticker: RCKT
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | RCKT | 3.05 | 0.33 | 0.08 | 17177 |
| 2025-08-18 | RCKT | 3.03 | 0.33 | 0.04 | 15954 |
| 2025-08-19 | RCKT | 2.92 | 0.33 | 0.05 | 16014 |
| 2025-08-20 | RCKT | 3.76 | 0.32 | 0.10 | 16120 |
| 2025-08-21 | RCKT | 3.73 | 0.28 | 0.07 | 21215 |
| 2025-08-22 | RCKT | 3.64 | 0.27 | 0.03 | 21432 |
| 2025-08-25 | RCKT | 3.54 | 0.27 | 0.07 | 21888 |
| 2025-08-26 | RCKT | 3.39 | 0.27 | 0.14 | 21915 |
| 2025-08-27 | RCKT | 3.32 | 0.27 | 0.02 | 21865 |
| 2025-08-28 | RCKT | 3.34 | 0.27 | 0.05 | 21951 |
| 2025-08-29 | RCKT | 3.28 | 0.27 | 1.13 | 21851 |
| 2025-09-02 | RCKT | 3.25 | 0.28 | 0.34 | 22085 |
| 2025-09-03 | RCKT | 3.33 | 0.28 | 0.23 | 22154 |
| 2025-09-04 | RCKT | 3.22 | 0.28 | 0.33 | 22260 |
| 2025-09-05 | RCKT | 3.28 | 0.28 | 1.91 | 22172 |
| 2025-09-08 | RCKT | 3.26 | 0.27 | 0.24 | 21996 |
| 2025-09-09 | RCKT | 3.21 | 0.27 | 0.00 | 21984 |
| 2025-09-10 | RCKT | 3.18 | 0.26 | 0.00 | 22077 |
| 2025-09-11 | RCKT | 3.28 | 0.26 | 0.38 | 22043 |
| 2025-09-12 | RCKT | 3.15 | 0.26 | 0.06 | 22056 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | RCKT | 3.05 | 32.4 | -27.7 | -2.05 |
| 2025-08-18 | RCKT | 3.03 | 27.1 | -17.7 | -2.05 |
| 2025-08-19 | RCKT | 2.91 | 27.1 | 72.4 | -2.05 |
| 2025-08-20 | RCKT | 3.75 | 27.1 | -260.0 | -2.05 |
| 2025-08-21 | RCKT | 3.73 | 27.1 | 38.9 | -2.05 |
| 2025-08-22 | RCKT | 3.65 | 27.1 | 47.8 | -2.05 |
| 2025-08-25 | RCKT | 3.55 | 27.4 | 51.5 | -2.12 |
| 2025-08-26 | RCKT | 3.39 | 27.4 | 62.7 | -2.12 |
| 2025-08-27 | RCKT | 3.32 | 27.4 | 50.2 | -2.12 |
| 2025-08-28 | RCKT | 3.35 | 27.4 | 30.3 | -2.12 |
| 2025-08-29 | RCKT | 3.28 | 27.4 | 50.4 | -2.12 |
| 2025-09-02 | RCKT | 3.25 | 27.4 | 43.3 | -2.11 |
| 2025-09-03 | RCKT | 3.33 | 27.4 | 64.9 | -2.11 |
| 2025-09-04 | RCKT | 3.23 | 27.4 | 97.3 | -2.11 |
| 2025-09-05 | RCKT | 3.28 | 27.4 | 72.0 | -2.11 |
| 2025-09-08 | RCKT | 3.26 | 27.4 | 85.3 | -2.11 |
| 2025-09-09 | RCKT | 3.21 | 27.4 | 89.4 | -2.11 |
| 2025-09-10 | RCKT | 3.18 | 27.4 | 86.6 | -2.11 |
| 2025-09-11 | RCKT | 3.28 | 27.4 | 61.0 | -2.11 |
| 2025-09-12 | RCKT | 3.16 | 27.4 | 103.1 | -2.11 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | RCKT | -0.27 | -15.17 | 11.37 |
| 2025-08-18 | RCKT | -0.27 | -20.92 | 11.35 |
| 2025-08-19 | RCKT | -0.61 | -20.92 | 11.36 |
| 2025-08-20 | RCKT | -0.61 | -20.92 | 11.36 |
| 2025-08-21 | RCKT | -0.66 | -20.92 | 11.36 |
| 2025-08-22 | RCKT | -0.66 | -20.92 | 11.36 |
| 2025-08-25 | RCKT | -0.66 | -15.97 | 11.36 |
| 2025-08-26 | RCKT | -0.36 | -15.97 | 11.36 |
| 2025-08-27 | RCKT | -0.36 | -15.97 | 11.86 |
| 2025-08-28 | RCKT | -0.08 | -15.97 | 11.86 |
| 2025-08-29 | RCKT | -0.08 | -15.97 | 11.86 |
| 2025-09-02 | RCKT | -0.08 | -15.93 | 11.86 |
| 2025-09-03 | RCKT | -0.08 | -15.93 | 11.86 |
| 2025-09-04 | RCKT | -0.08 | -15.93 | 11.86 |
| 2025-09-05 | RCKT | -0.08 | -15.93 | 11.86 |
| 2025-09-08 | RCKT | -0.08 | -15.85 | 11.86 |
| 2025-09-09 | RCKT | -0.08 | -15.85 | 11.86 |
| 2025-09-10 | RCKT | -0.08 | -15.85 | 11.86 |
| 2025-09-11 | RCKT | -0.08 | -15.85 | 15.66 |
| 2025-09-12 | RCKT | -0.08 | -15.85 | 15.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPSā
-0.59
Avg. EPS Est. Current Quarter
-0.52
Avg. EPS Est. Next Quarter
-0.46
Insider Transactions
-0.08
Institutional Transactions
-15.85
Beta
0.6
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
11
Growth Score
22
Sentiment Score
20
Actual DrawDown %
95.3
Max Drawdown 5-Year %
-96.5
Target Price
7.86
P/E
Forward P/E
PEG
P/S
P/B
0.96
P/Free Cash Flow
EPS
-2.5
Average EPS Est. Cur. Yā
-2.11
EPS Next Y. (Est.)
-1.19
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.45
Return on Equity vs Sector %
-97.5
Return on Equity vs Industry %
-84.4
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
0.03
EBIT Estimation
103.1
Rocket Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 299
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones EnergĆ©ticas, Medioambientales y TecnolĆ³gicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
stock quote shares RCKTĀ – Rocket Pharmaceuticals, Inc. Stock Price stock today
news today RCKTĀ – Rocket Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RCKTĀ – Rocket Pharmaceuticals, Inc. yahoo finance google finance
stock history RCKTĀ – Rocket Pharmaceuticals, Inc. invest stock market
stock prices RCKT premarket after hours
ticker RCKT fair value insiders trading